Qiagen announced a collaboration with Eli Lilly and Co. to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen’s multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.
{iframe}http://www.dddmag.com/news/2014/05/qiagen-lilly-launch-cancer-biomarker-analysis-project{/iframe}